作为诊断生物标志物和炎症性肠道疾病的治疗标,加勒-3的可行性
Xianglin Pan1, Li Luo2, Minni Wang3
1Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, 430014, China; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, Hubei, 442000, China.
European journal of pharmacology
|August 6, 2025
概括
加勒-3 (Gal-3) 涉及炎症性肠病 (IBD) 病原发生. 这篇评论探讨了Gal-3的情况.
科学领域:
- 胃肠道学和免疫学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎和克罗恩病,存在诊断和治疗方面的挑战.
- 肠道细胞中的一种蛋白质加勒-3 (Gal-3),因其在免疫调节和炎症中的作用而越来越受认可.
- 了解Gal-3的功能对于推进IBD管理至关重要.
研究的目的:
- 在IBD的背景下审查Gal-3的结构,功能和表达.
- 综合目前关于Gal-3在IBD病变发生中的作用的研究.
- 批判性地评估发现中的差异,并评估Gal-3作为生物标志物和治疗点的潜力.
主要方法:
- 文献综述综合了有关Gal-3和IBD的现有研究.
- 分析肠道组织中的Gal-3表达模式.
- 批判性地检查有关Gal-3的炎症作用的相互矛盾的研究结果.
主要成果:
- -3在与IBD相关的肠上皮和免疫细胞中表达.
- 有证据表明,Gal-3在IBD病变发生过程中起着促炎作用,尽管一些研究报告了相互矛盾的结果.
- 差异可能源于研究模型,方法和疾病背景的变化.
结论:
- -3是IBD肠道炎症的关键调节器.
- 需要进一步的研究来协调相互矛盾的发现,并澄清Gal-3的确切作用.
- -3具有作为IBD的诊断生物标志物和治疗点的潜力.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
233
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
233
Inflammatory Bowel Disease IV: Pharmacological Management
190
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
190


